Needham Reiterates Buy on Biogen, Maintains $294 Price Target
RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
Biogen Analyst Ratings
RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
Wedbush Adjusts Price Target on Biogen to $215 From $219
Biogen Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)
Royal Bank of Canada: Biogen (BIIB.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $317.00.
Biogen Analyst Ratings
RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)
Biogen's Strategic Diversification and Financial Strategy Garner Outperform Rating
Strategic Acquisitions and Clinical Catalysts Bolster Biogen's Buy Rating
Biogen (BIIB) Gets a Buy From Oppenheimer
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)
HC Wainwright & Co. : Biogen (BIIB.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $300.00.
Biogen Analyst Ratings
Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating
Biogen Analyst Ratings